Investigating Efficacy and Safety of Novel and Emerging Dengue Vaccination Options

This activity is part of a series


Marco Aurélio P. Sáfadi, MD, PhD
Associate Professor and Head, Department of Pediatrics
Santa Casa de São Paulo School of Medical Sciences
São Paulo, Brazil
Marco Aurélio P. Sáfadi, MD, PhD

Prof. Sáfadi is the Head of the Department of Pediatrics at the School of Medical Sciences of Santa Casa de São Paulo and serves as the Coordinator of the post-graduation course on Health Sciences there. Following his medical degree and a residency in pediatrics, he continued his training in pediatric infectious diseases at the Federal University of São Paulo, receiving a master’s and a PhD degree.

Prof. Sáfadi has been a member of the Permanent Advisory Board on Immunization Practices for the Secretary of Health in the State of São Paulo and the Ministry of Health in Brazil for more than 10 years. He is the current Chairman of the Department of Immunization for the Society of Pediatrics, São Paulo as well as the Chairman of the Department of Infectious Diseases for the Brazilian Society of Pediatrics.

Prof. Sáfadi is an active member of several societies focusing on infectious diseases, including SLIPE, ESPID, and WSPID. He is also a member of the Steering Committee from the Global Meningococcal Initiative and a member of the Scientific Advisory Group of the Confederation of Meningitis Organisations (CoMO), which is part of the Meningitis Research Foundation. Prof. Sáfadi is an expert member of the SAGE Working Group on Meningococcal Vaccines and Vaccination from WHO and a liaison representative for the Brazilian NITAG in the SAGE Immunization Group from WHO. He was nominated as a member to the Coalition for Epidemic Preparedness Innovations (CEPI) Scientific Advisory Committee.

Prof. Sáfadi is a member of the editorial board from Jornal de Pediatria, Pneumonia BMC and The Journal of Pediatrics. Over the course of his career, he has made significant contributions to the field of infectious diseases, particularly in the areas of immunization, meningococcal and pneumococcal infections, congenital toxoplasmosis, influenza, rotavirus gastroenteritis, HPV, and community-acquired infections. He has published over 100 peer-reviewed articles and has presented his research at numerous international conferences. He is passionate about sharing his expertise with others and is committed to advancing the field through education and research.

Inés O. Esquilín Rivera, MD
Professor, Department of Pediatrics
Director, Pediatric Infectious Diseases Division
University of Puerto Rico School of Medicine
Medical Sciences Campus
San Juan, PR
Inés O. Esquilín Rivera, MD

Dr. Inés Esquilín Rivera is a professor at the Department of Pediatrics of the University of Puerto Rico School of Medicine and the director of the Division of Pediatric Infectious Diseases.

She obtained her doctorate degree in Medicine and Pediatrics at the University of Puerto Rico School of Medicine in 1989 and 1992, respectively. Subsequently, she completed a Pediatric Infectious Disease Fellowship at the Jackson Memorial Hospital affiliated with the University of Miami in Florida in 1995.

She is involved in clinical research projects involving vaccine development, epidemiology of arboviral diseases, HIV-related conditions, and antiretroviral medications.

Dr. Esquilín Rivera  worked as the principal investigator of two phase II studies for investigational dengue vaccines from 2007 to 2017. The results of these studies were published in peer-reviewed journals and have multiple citations.

She was a member of the CDC ACIP Dengue Vaccines Workgroup from October 2018 to 2022 and works with the Puerto Rico Health Department in the development of strategies to facilitate dengue vaccination on the island. She has been a member of the WHO/PAHO Arboviral Group Advisory Board since 2017 and has participated in multiple educational activities related to the prevention of dengue and other arboviral diseases.

Statement of Need

Currently, there is only one FDA-approved vaccination against dengue disease available, and there are specific requirements and limitations on who can access and benefit from this vaccine. Most notably, the vaccine is only available to children aged 9-16 in endemic areas who also have laboratory-confirmed previous dengue infection. While the currently available vaccination against dengue disease has limited scope and application, there are several dengue vaccine candidates in clinical trials. It is imperative that clinicians practicing in endemic areas as well as areas with newer local outbreaks understand how the management, treatment, and prevention of dengue disease will change as new vaccinations are approved.

In the final activity of this CME Outfitters Snack, expert faculty will provide an overview of the latest efficacy and safety data for both current and emerging vaccinations against dengue disease as well as assist learners in the translation of this data into clinical practice.

Learning Objective

Incorporate latest efficacy and safety data of current and emerging dengue disease vaccination options into clinical practice.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists specializing in travel medicine, public health, infectious disease, or primary care.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-067-H01-P

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Sáfadi reports the following financial relationships:

Advisory Board and Consultant: MSD; Sanofi; and Takeda Pharmaceutical Company Limited

Dr. Esquilín Rivera reports no financial relationships to disclose.

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

  • Cristina Rivera Carpenter, PhD, MSN, RN (peer reviewer)
  • Morgan Stockberger, MD (planning committee)
  • John Jones, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Investigating Efficacy and Safety of Novel and Emerging Dengue Vaccination Options
Event Date: 08/18/2023 at 4:00 am EST